Psoriasis Therapies: Long-Term Data on Bimekizumab & Brodalumab – 2026 Update

Fresh data presented at Maui Derm 2026 continue to demonstrate lasting benefits of the biologic medication bimekizumab (Bimzelx, UCB) for individuals managing psoriasis, with consistent and substantial improvements observed through five years of treatment. This extended follow-up offers reassurance regarding the durability of response for patients who have found relief with this therapy, and provides valuable insight into long-term safety.

Psoriasis is a chronic autoimmune disease that affects the skin, causing raised, red, scaly patches. These patches can be itchy, painful, and disfiguring, significantly impacting quality of life. Treatment options range from topical creams and light therapy to systemic medications, including biologics like bimekizumab, which target specific parts of the immune system to reduce inflammation. The challenge with many systemic treatments is maintaining efficacy over the long term, and understanding potential long-term safety concerns.

Long-Term Efficacy and Safety Data

James Song, MD, FAAD, Co-CMO, highlighted the five-year data during his presentation. According to Dr. Song, director of clinical research at Frontier Dermatology in Mill Creek, Washington, the results display “very consistent, deep and durable responses through the 5-year mark.” This suggests that, for many patients, the initial improvements seen with bimekizumab are not simply temporary, but are sustained over an extended period. Previous research indicated bimekizumab as a preferred option for patients needing a new biologic for psoriasis, and these new findings reinforce that position.

Bimekizumab works by selectively blocking interleukin-17A and interleukin-17F, two key proteins involved in the inflammatory processes that drive psoriasis. Unlike some other biologics that target a broader range of immune pathways, this targeted approach may contribute to its sustained efficacy and favorable safety profile. It’s important to note that individual responses to treatment can vary, and not everyone will experience the same level of benefit.

Brodalumab for Refractory Cases

Dr. Song also discussed brodalumab (Siliq, Ortho Dermatologics) as an alternative treatment option, particularly for patients whose psoriasis doesn’t respond adequately to other therapies. He presented seven-year safety data for brodalumab, providing further information about its long-term tolerability. Brodalumab targets the interleukin-17 receptor, offering another avenue for suppressing the immune response in psoriasis. The Social Security Administration warns about scams, and it’s important to verify any health information with a trusted medical professional.

Understanding Treatment Options and Refractory Disease

“Refractory disease” refers to conditions that do not respond to standard treatments. In the context of psoriasis, this means that patients have tried multiple therapies without achieving sufficient control of their symptoms. Identifying effective treatments for refractory psoriasis is a significant clinical challenge, as these patients often experience a substantial burden of disease. The availability of options like brodalumab provides clinicians with additional tools to address this unmet need.

It’s crucial for patients to have open and honest conversations with their dermatologists about their treatment goals and expectations. Factors to consider when choosing a treatment include the severity of psoriasis, previous treatment history, potential side effects, and individual preferences. A personalized approach to treatment is essential for optimizing outcomes.

What the Data Doesn’t Tell Us

While the five-year data for bimekizumab are encouraging, it’s important to acknowledge the limitations of the available evidence. Long-term studies often face challenges with patient retention, meaning that some participants may drop out over time. This can introduce bias into the results, as those who remain in the study may not be representative of the entire patient population. The studies typically follow patients for a defined period, but psoriasis is a lifelong condition, so the very longest-term effects remain to be seen.

The data also don’t provide information about the potential for developing resistance to bimekizumab over time. While the current data suggest durable responses, it’s possible that some patients may eventually experience a loss of efficacy. Ongoing monitoring and research are needed to assess this risk.

The Role of Clinical Trials and Ongoing Research

The findings presented at Maui Derm 2026 underscore the importance of continued research in psoriasis. Clinical trials are essential for evaluating the efficacy and safety of new treatments, as well as for gaining a deeper understanding of the disease itself. LastPass recently alerted customers to phishing campaigns, highlighting the need for vigilance regarding online security, including health-related information.

Researchers are also exploring new therapeutic targets and approaches, including personalized medicine strategies that tailor treatment to the individual characteristics of each patient. Advances in genomics and immunology are paving the way for more precise and effective therapies.

Looking Ahead: Surveillance and Guidance Updates

The ongoing collection of real-world data through post-market surveillance programs will be crucial for monitoring the long-term safety and effectiveness of bimekizumab and other psoriasis treatments. These programs involve tracking patient outcomes over time and identifying any potential safety signals. Regulatory agencies, such as the Food and Drug Administration (FDA), use this data to update treatment guidelines and ensure that patients have access to the safest and most effective therapies. Plug Power is scheduled to ring the Nasdaq closing bell on March 6, 2026, an unrelated event but demonstrating the ongoing flow of information and events.

As new evidence emerges, treatment guidelines are likely to evolve. Patients and healthcare providers should stay informed about the latest recommendations and incorporate them into clinical decision-making. Open communication and a collaborative approach are essential for optimizing psoriasis management.